- Home
- VFC vs MRUS Comparison
VFC vs MRUS Comparison
Compare VFC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFC
- MRUS
- Stock Information
- Founded
- VFC 1899
- MRUS 2003
- Country
- VFC United States
- MRUS Netherlands
- Employees
- VFC N/A
- MRUS N/A
- Industry
- VFC Apparel
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- VFC Consumer Discretionary
- MRUS Health Care
- Exchange
- VFC Nasdaq
- MRUS Nasdaq
- Market Cap
- VFC 5.6B
- MRUS 5.1B
- IPO Year
- VFC N/A
- MRUS 2016
- Fundamental
- Price
- VFC $14.19
- MRUS $94.80
- Analyst Decision
- VFC Buy
- MRUS Buy
- Analyst Count
- VFC 17
- MRUS 18
- Target Price
- VFC $16.88
- MRUS $93.72
- AVG Volume (30 Days)
- VFC 8.2M
- MRUS 2.1M
- Earning Date
- VFC 10-28-2025
- MRUS 10-31-2025
- Dividend Yield
- VFC N/A
- MRUS N/A
- EPS Growth
- VFC N/A
- MRUS N/A
- EPS
- VFC 0.23
- MRUS N/A
- Revenue
- VFC $9,541,055,000.00
- MRUS $56,606,000.00
- Revenue This Year
- VFC $1.57
- MRUS $52.81
- Revenue Next Year
- VFC $2.49
- MRUS N/A
- P/E Ratio
- VFC $61.15
- MRUS N/A
- Revenue Growth
- VFC N/A
- MRUS 57.54
- 52 Week Low
- VFC $9.41
- MRUS $33.19
- 52 Week High
- VFC $29.02
- MRUS $95.30
- Technical
- Relative Strength Index (RSI)
- VFC 45.31
- MRUS 77.31
- Support Level
- VFC $13.64
- MRUS $94.59
- Resistance Level
- VFC $16.94
- MRUS $95.10
- Average True Range (ATR)
- VFC 0.71
- MRUS 0.32
- MACD
- VFC -0.12
- MRUS -0.97
- Stochastic Oscillator
- VFC 16.51
- MRUS 43.89
About VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.